Target · Tau
Tau
Tau pathology tracks cognitive decline more closely than amyloid; spread follows predictable Braak staging patterns.
All 17 claims
Sorted by confidence. Click any to read the evidence.
Pericyte loss in cognitive-impairment-prone hippocampal regions precedes blood-brain barrier breakdown and is detectable before clinical Alzheimer disease symptom onset; this provides a timing-window for biomarker-driven intervention.
In DIAN-TU, gantenerumab and solanezumab did not significantly slow cognitive decline in autosomal-dominant AD mutation carriers despite reducing biomarker targets; negative results suggest treatment initiation may need to begin earlier in the disease cascade.
Donanemab in TRAILBLAZER-ALZ 4 demonstrates that early tau burden (low/medium tau PET) selects for greater clinical benefit; donanemab-treated participants with low/medium tau showed 35% slower iADRS decline vs. placebo at 18 months, underscoring importance of biomarker-based patient selection.
Donanemab (anti-pyroglutamate-Aβ MAb) shows positive primary endpoint in early symptomatic AD with low/medium tau PET burden. Tau PET stratification meaningfully modifies treatment effect — high-tau subgroup shows attenuated benefit. ARIA-E rate ~24%; APOE4-dose-dependent.
Donanemab slowed clinical decline in early symptomatic Alzheimer's disease in TRAILBLAZER-ALZ 2, with efficacy interpreted against amyloid and tau-selection criteria.
TRAILBLAZER-ALZ 3 (NCT05026866): Tau PET and amyloid PET dual-enrichment; donanemab dosing until amyloid clearance confirmed.
TRAILBLAZER-ALZ Phase II (NCT03367403): Significant slowing of iADRS decline (−6.86 vs −10.06); rapid and near-complete amyloid clearance confirmed.
Lecanemab reduced amyloid burden and shifted downstream biomarkers in CLARITY AD, but biomarker movement remained larger than the observed clinical effect.
Immunotherapies Targeting Amyloid and Tau Protein in Alzheimer's Disease: Should We Move Away from Diseases and Focus on Biological Targets? A Systematic Review and Expert Opinion.
Posttreatment Amyloid Levels and Clinical Outcomes Following Donanemab for Early Symptomatic Alzheimer Disease: A Secondary Analysis of the TRAILBLAZER-ALZ 2 Randomized Clinical Trial. — ImportanceAccumulation of amyloid plaque drives pathogenesis of Alzheimer disease (AD). Reduction of amyloid via...
Recent Advances in Antibody Therapy for Alzheimer's Disease: Focus on Bispecific Antibodies. — Alzheimer's disease (AD) impacts more than half a million people worldwide, with no cure available. The regulatory approval of three anti-amyloid monoclonal antibodies (mAbs), including aducanumab, lecanemab, and...
Anti-Amyloid Monoclonal Antibodies for Alzheimer's Disease: Evidence, ARIA Risk, and Precision Patient Selection. — Alzheimer's disease (AD) is the most common cause of dementia, pathologically defined by extracellular amyloid-β (Aβ) plaques and intracellular tau neurofibrillary tangles. Recent U.S. Food and Drug...
Review of Donanemab and Lecanemab in Mild Dementia Stage of Alzheimer's Disease: Progress and Challenges. — Alzheimer's disease (AD) is a progressive neurodegenerative disorder marked by cognitive decline and functional impairment, primarily driven by the accumulation of amyloid-beta (Aβ) plaques and tau tangles....
What public dataset can link individual amyloid clearance, tau progression, ARIA events, and cognitive trajectories across antibody programs?
Does earlier intervention before tau spread materially change the clinical effect size of anti-amyloid therapy?
Which public patient-level dataset can jointly inspect amyloid clearance, tau movement, ARIA events, APOE4 status, and cognitive trajectory after anti-amyloid treatment?
If tau is the stronger correlate of decline, why have anti-amyloid therapies (lecanemab, donanemab) shown clinical benefit while anti-tau therapies have largely failed?